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Background. To expedite the evaluation of vaccines against paratyphoid fever, we aimed to develop the first human challenge 
model of Salmonella enterica serovar Paratyphi A infection.
Methods. Two groups of 20 participants underwent oral challenge with S. Paratyphi A following sodium bicarbonate pretreat-
ment at 1 of 2 dose levels (group 1: 1–5 × 103 colony-forming units [CFU] and group 2: 0.5–1 × 103 CFU). Participants were moni-
tored in an outpatient setting with daily clinical review and collection of blood and stool cultures. Antibiotic treatment was started 
when prespecified diagnostic criteria were met (temperature ≥38°C for ≥12 hours and/or bacteremia) or at day 14 postchallenge.
Results. The primary study objective was achieved following challenge with 1–5 × 103 CFU (group 1), which resulted in an 
attack rate of 12 of 20 (60%). Compared with typhoid challenge, paratyphoid was notable for high rates of subclinical bacteremia 
(at this dose, 11/20 [55%]). Despite limited symptoms, bacteremia persisted for up to 96 hours after antibiotic treatment (median 
duration of bacteremia, 53 hours [interquartile range, 24–85 hours]). Shedding of S. Paratyphi A in stool typically preceded onset 
of bacteremia.
Conclusions. Challenge with S. Paratyphi A at a dose of 1–5 × 103 CFU was well tolerated and associated with an acceptable 
safety profile. The frequency and persistence of bacteremia in the absence of clinical symptoms was notable, and markedly different 
from that seen in previous typhoid challenge studies. We conclude that the paratyphoid challenge model is suitable for the assess-
ment of vaccine efficacy using endpoints that include bacteremia and/or symptomatology.
Clinical Trials Registration. NCT02100397.
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Efforts aimed at reducing the global burden of enteric 
fever are likely to require a coordinated strategy compris-
ing improvements in water quality, sanitation, and hygiene 
measures along with the development of effective vaccines. 
While Salmonella enterica serovar Typhi remains the prin-
cipal etiological agent of enteric fever globally, Salmonella 
enterica serovar Paratyphi A (S. Paratyphi A) is responsible 
for an increasing proportion of enteric fever cases. In South 
and Southeast Asia, annual incidence rates in some areas 
are estimated to be as high as 150 cases per 100 000 per-
son-years [1].
Relatively little is known regarding the pathophysiology 
and host response to S. Paratyphi A  infection. Salmonella 
Typhi and Paratyphi A  possess similar genomic markers of 
host restriction, but differ with regards to expression of cer-
tain virulence factors, such as the lack of Vi polysaccharide 
capsule expression by S. Paratyphi A/B [2, 3]. Additionally, 
there are currently no licensed vaccines available for the pre-
vention of paratyphoid fever. The licensed S. Typhi vaccine 
Ty21a can induce cross-reactive humoral immune responses 
to S. Paratyphi A/B in vitro, and there is some evidence from 
field trials for cross-protection against S. Paratyphi B [4, 5]. 
Several promising vaccine candidates are in development, 
including live-attenuated strains and conjugate vaccines 
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targeted against the O-specific polysaccharide (O:2) of S. 
Paratyphi A, although no candidate vaccines have undergone 
efficacy trials to date [6]. Development of vaccines to prevent 
paratyphoid infection is hampered by limited knowledge of 
immunological correlates of protection and the lack of a suit-
able small-animal model of infection.
Human challenge studies are increasingly used to identify 
promising vaccine candidates suitable for evaluation in large-
scale field trials [7]. In this study, we sought to establish an S. 
Paratyphi A human challenge model in healthy adult volunteers 
by oral challenge to enable future assessment of S. Paratyphi 
A  vaccines and to assess host–pathogen interactions under a 
strictly controlled setting.
METHODS
Study Design
We performed an observational, dose-level modification 
human challenge study of S. Paratyphi A infection conducted in 
healthy community adult volunteers, at the Centre for Clinical 
Vaccinology and Tropical Medicine, University of Oxford, 
United Kingdom [8]. Description of the study protocol and 
enrollment criteria are detailed elsewhere [9, 10].
The primary objective of the study was to determine the 
dose in colony-forming units (CFU) of S. Paratyphi A  strain 
NVGH308 required to achieve an attack rate of 60%–75%, 
when ingested with sodium bicarbonate solution to neutralize 
gastric acid.
Challenge Strain
Salmonella Paratyphi A strain NVGH308 was isolated in 2006 
from a patient with paratyphoid fever in Kathmandu, Nepal, 
and is susceptible to most commonly used antibiotics, includ-
ing ciprofloxacin (Supplementary Table 1) [9]. The NVGH308 
strain was selected as it is a contemporary, circulating strain iso-
lated from a patient in a highly endemic country.
Whole-genome sequencing was undertaken to identify the 
phylogenetic relationship of NVGH308 to other circulating 
strains (Supplementary Figure 1; Supplementary Methods).
The challenge inoculum was freshly prepared on day of 
challenge (Supplementary Methods). An initial target dose of 
1–5 × 103 CFU (group 1) was selected based upon prior S. Typhi 
challenge studies in a similar study population [11]. Following 
fulfillment of the primary objective at the initial target dose, 
we amended the original study protocol to include a dose de- 
escalation group (0.5–1 × 103 CFU; group 2)  to affirm a rela-
tionship between dose and diagnostic endpoints.
Clinical Evaluation
Regular participant safety monitoring occurred through daily 
clinical review for a minimum of 14 days and included solicited 
symptoms (Supplementary Table  2) and twice-daily tempera-
ture measurements [9].
Diagnostic Criteria
The primary outcome was the rate of paratyphoid infection, 
defined as a positive blood culture for S. Paratyphi A (taken ≥72 
hours after challenge to avoid detection of primary bacteremia) 
and/or oral temperature ≥38°C persisting for ≥12 hours [9]. 
Treatment was initiated upon fulfillment of diagnostic criteria 
(or at day 14 for those without illness) and comprised oral cip-
rofloxacin 500 mg twice daily for 14 days.
Serological Response
Blood was collected at baseline and days 10, 28, and 90 
post-challenge. Specific immunoglobulin M (IgM), immuno-
globulin G (IgG), and immunoglobulin A (IgA) to S. Paratyphi 
A lipopolysaccharide (LPS) and flagellin (H) were measured by 
an in-house enzyme-linked immunosorbent assay using goat 
antihuman IgM, IgG, and IgA conjugated to horseradish perox-
idase (Supplementary Methods).
Statistical Analysis
All participants were included in the primary analysis and a 
post hoc analysis was conducted comparing participants chal-
lenged with S. Paratyphi A in this study with those challenged 
with S. Typhi in our previous study [11].
Clinical, laboratory, and immunological data were col-
lated using a clinical trials database (OpenClinica, version 
3.1). Data analysis was performed as described in detail in the 
Supplementary Methods, using R version 3.2.2 [12].
RESULTS
Forty healthy adult participants were enrolled into the 
study between 20 May and 20 November 2014 (Table  1; 
Supplementary Figure 2). Twenty participants were challenged 
with S. Paratyphi A at a target dose of 1–5 × 103 CFU (group 
1). A second group of 20 participants was challenged at a target 
dose of 0.5–1.0 × 103 CFU (group 2).
Paratyphoid infection was diagnosed in 50% (20/40) of all par-
ticipants challenged. The primary study objective was achieved 
in challenge group 1, where 12 of 20 participants met the pre-
specified diagnostic criteria for paratyphoid fever (attack rate, 
60%; 95% confidence interval [CI], 36%–81%) (Figure 1). Eleven 
participants (11/12 [92%]) in this group were diagnosed follow-
ing a positive blood culture for S. Paratyphi A and 1 participant 
was diagnosed based on temperature criteria with subsequent 
blood culture confirmation. Median time from challenge to ini-
tiation of treatment was 6.4 days (range, 5.9–8.3 days) (Table 2).
Paratyphoid infection was diagnosed less frequently in chal-
lenge group 2. In this group, 8 of 20 participants met the pre-
specified diagnostic criteria following challenge (attack rate, 
40%; 95% CI, 19%–64%), all of whom were diagnosed following 
a positive blood culture (Table 2). Median time from challenge 
to initiation of treatment was 8.3  days (range, 7.1–12.0  days) 
(Figure 1).
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Attack rates using alternative diagnostic criteria are outlined 
in Table 2. The hypothetical attack rate was lower in both study 
groups if clinical endpoints alone (eg, fever) were used to define 
paratyphoid disease.
All participants were managed with daily clinical review and 
no participants met the prespecified criteria for severe enteric 
fever [9]. Two participants had positive stool cultures for S. 
Paratyphi A  after completing a 14-day course of ciprofloxacin, 
neither of whom had evidence of gallbladder disease at screen-
ing. Both were successfully re-treated with a 14-day course of 
oral azithromycin (500 mg daily), and all subsequent clearance 
stools were negative. There were no episodes of relapse of clinical 
disease [9]. One serious adverse event was recorded (appendi-
citis 6 months after S. Paratyphi A challenge) and was assessed 
as being unrelated to study procedures. One participant devel-
oped mouth ulcers after treatment with ciprofloxacin, which 
resolved following a change to azithromycin. A second partici-
pant developed vaginal candidiasis following antibiotic treatment 
(ciprofloxacin), which resolved following treatment with topical 
clotrimazole.
The most common symptom reported by those with paraty-
phoid illness was headache (17/20 [85%]), followed by malaise 
(15/20 [75%]), abdominal pain (14/20 [70%]), and myal-
gia (14/20 [70%]). The majority of solicited symptoms were 
graded as mild and did not result in limitation of usual activity 
(Figure 1; Supplementary Table 2). In comparison with partic-
ipants challenged with S. Typhi in earlier studies [11], paraty-
phoid resulted in a milder symptom profile, characterized by 
fewer severe symptoms and lower cumulative symptom scores 
(Figure 2; Supplementary Table 3).
Table 1. Participant Demographic Characteristics
Characteristic Group 1 Group 2 All
No. of participants  
challenged
20 20 40
Sex, male 10 (50) 11 (55) 21 (52.5)
Age, y, median (range) 27 (19–49) 23 (20–50) 25 (19–50)
Ethnicity, white British 18 (90) 17 (85) 35 (88)
Country of birth, United 
Kingdom
15 (75) 17 (85) 32 (80)
Tobacco smoking ever, yes 9 (45) 8 (40) 17 (43)
Alcohol intake, units/wk, 
median (IQR)
4 (0–10) 7 (4–11) 5 (2–10)
BMI, kg/m2, mean ± SD 23.5 ± 3.2 22.8 ± 4.2 24.1 ± 3.8
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation.
Figure 1. A, Kaplan-Meier plots indicating time to diagnostic endpoints: time to diagnosis (i) and time to first temperature ≥38°C (ii). B, Clinical symptom profiles following 
Salmonella Paratyphi A challenge. Percentage of participants reporting solicited systemic symptoms on 1 or more days following S. Paratyphi A challenge, recorded using an online 
diary for 21 days. Stacked columns display percentage of participants reporting maximum symptom severity as mild, moderate, or severe. (i) Individuals meeting prespecified criteria 
for paratyphoid disease in group 1 and group 2. (ii) Individuals who did not meet prespecified criteria for paratyphoid disease in group 1 and group 2. None, no reported symptoms; 
mild, present but no limitation of usual activity; moderate, some limitation of daily activity; severe, unable to perform normal daily activity. Abbreviation: CFU, colony-forming units.
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Laboratory parameters were in keeping with those 
expected for acute enteric fever (Supplementary Figure  3) 
[13]. Among those meeting diagnostic endpoints, peripheral 
blood biochemistry demonstrated elevated C-reactive 
protein and alanine aminotransferase, while hematology 
revealed a modest fall in hemoglobin, neutrophil, and lym-
phocyte counts.
We documented at least 1 positive blood culture in all par-
ticipants diagnosed with paratyphoid (20/20 [100%]; median 
number of positive blood cultures, 5.5; range, 1–8). Median 
bacteremia clearance times were 2.2  days (interquartile range 
[IQR], 1–3.5  days) for S. Paratyphi (Figures 2 and 3). The 
median time from challenge to bacteremia was 5.2 days (IQR, 
5.0–6.4 days) in group 1 and 7 days (IQR, 6.7–7.4 days) in group 
2.  Quantitative blood cultures performed prior to antibiotic 
treatment demonstrated median bacterial loads of 1.1 CFU/
mL (range, 0–4.1 CFU/mL) in group 1 and 0.2 CFU/mL (range, 
0–6.9 CFU/mL) in group 2 participants, which are comparable 
to those seen in cases of typhoid fever in earlier challenge stud-
ies and in endemic settings [11, 14]. The rate of blood culture 
positive days was twice as high in S. Paratyphi A–diagnosed 
participants than in S. Typhi–diagnosed participants from our 
previous study (incidence rate ratio [IRR], 2.1; 95% CI, 1.46–
3.1; P < .001) (Figure 2; Table 2).
Subclinical bacteremia was a common finding following chal-
lenge, with 11 of 20 (55%; 95% CI, 32%–77%) participants hav-
ing demonstrable bacteremia but remaining persistently afebrile 
following challenge, although other symptoms were observed as 
discussed above (Supplementary Table 2). Afebrile bacteremia 
was less common in earlier typhoid challenge studies performed 
by our group (4/21 [19%]; 95% CI, 5%–42%; P = .025, Fisher 
exact test) [11]. Fever was recorded less frequently in group 2 
(2/8 [25%]) than in group 1 (7/12 [58%]) (Table 2).
Shedding of S. Paratyphi A  in stool occurred sporadically 
throughout the challenge period, and at least 1 stool culture 
was positive in 17 of 40 participants (43%; 95% CI, 27%–59%) 
(Figure  3). Among participants with demonstrable bacter-
emia, 11 of 20 (55%; 95% CI, 32%–77%) had a positive stool 
culture for at least 1 time point and stool shedding frequently 
preceded the onset of bacteremia (Figure  3). Asymptomatic 
shedding was identified in 6 of 20 participants (30%; 95% CI, 
12%–54%) who did not reach the diagnostic criteria during the 
observation period. The rate of stool positivity was similar in 
S. Paratyphi A–diagnosed participants as was observed previ-
ously in S. Typhi–diagnosed participants (IRR, 0.78; 95% CI, 
.40–1.52; P = .457).
Baseline anti-LPS IgG geometric mean concentrations were 
higher in undiagnosed participants prior to challenge (P = 
.034) (Supplementary Figure 4). Anti-LPS antibody responses 
peaked at day 28 postchallenge and were significantly higher 
in those diagnosed with paratyphoid compared with those 
without acute disease (P < .001). In contrast, anti-H anti-
body responses were only marginally increased above base-
line at D28 and only in those meeting diagnostic endpoints 
(Supplementary Figure 4).
Table 2. Attack Rates and Response to Salmonella Paratyphi A Challenge
Results
Group 1
(n = 20)
Group 2
(n = 20)
All
(N = 40)
Target challenge dose, CFU 1–5 × 103 0.5–1 × 103 …
Attack rate, No. (% total) 
(95% CI)
12 (60)
(36–81)
8 (40)
(19–64)
20 (50)
(34–66)
Actual challenge dose, CFU × 
103, median (range)
2.4 (2.2–2.8) 0.9 (0.7–1.3) …
 Paratyphoid A diagnosed 2.4 (2.2–2.7) 1.0 (0.7–1.3) …
 Paratyphoid A not diagnosed 2.5 (2.3–2.7) 0.8 (0.7–1.3) …
Actual challenge dose/body 
surface areaa, CFU/m2, 
mean ± SD
1350 ± 166 519 ± 163 …
 Paratyphoid A diagnosed 1336 ± 196 533 ± 171 …
 Paratyphoid A not diagnosed 1371 ± 119 509 ± 165 …
Mode of diagnosis, No. (% total)
 Temperature ≥38°C for 
≥12 h with blood culture 
confirmation
1 (5) 0 (0) 1 (2.5)
 Microbiological diagnosisb 11 (55) 8 (40) 19 (47.5)
Bacteraemia, No. (% total) 12 (60) 8 (40) 20 (50)
 Time to bacteremiac, d, 
median (IQR)
5.2 (5.0–6.4) 7 (6–11) 6.1 (5.1–7.1)
 Time to antibioticsd, d, 
median (IQR)
6.4 (6.2–7.4) 8.3 (8.2–9.2) 8.0 (6.4–8.3)
 Overall duration of bactere-
miae, d, median (IQR)
4.1 (3.4–5.0) 1.0 (1.0 -3.4) 4.0 (1.1–4.9)
Clearance timef, d, median 
(IQR)
2.9 (2.1–3.6) 0.9 (0.7–1.9) 2.2 (1.0–3.5)
Quantitative blood culture, CFU/
mL, median (range)
1.1 (0–4.1) 0.2 (0–6.9) 1 (0–6.9)
Temperature ≥38°C (any dura-
tion)g, No. (% total)
7 (35) 2 (10) 9 (45)
 Paratyphoid A diagnosed 7 (35) 2 (10) 9 (45)
 Paratyphoid A not diagnosed 0 (0) 0 (0) 0 (0)
Stool shedding, No. (% total) 12 (60) 4 (20) 16 (40)
 Paratyphoid A diagnosed 8 (40) 2 (10) 10 (25)
 Paratyphoid A not diagnosed 4 (20) 2 (10) 6 (15)
Attack rates using alternative diagnostic criteria
 Temperature ≥37.5°C (any 
duration), No. (% total)
8 (40) 4 (20) 12 (30)
 Temperature ≥38°C (any 
duration), No. (% total)
7 (35) 2 (10) 9 (45)
 Temperature ≥37.5°C (any 
duration) and positive 
blood culture
7 (35) 4 (20) 11 (27.5)
 Temperature ≥38°C (any 
duration) and positive 
blood culture
7 (35) 2 (10) 9 (22.5)
Abbreviations: CFU, colony-forming units; CI, confidence interval; IQR, interquartile range; 
SD, standard deviation.
aBody surface area (BSA) calculated according to Mosteller method: BSA (m2) = (height in 
cm × weight in kg / 3600) × 0.5. 
bSalmonella Paratyphi A isolated from blood culture taken ≥72 h from challenge.
cTime from challenge to collection of first positive blood culture.
dTime from ingestion of the challenge agent to the fulfillment of diagnostic criteria.
eTime from collection of first positive blood culture to collection of first persistently 
negative blood culture.
fTime from initiation of antibiotics to collection of first persistently negative blood culture.
gDay 0 (day of challenge) to day 14.
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DISCUSSION
In 1909, Proescher reported a case of “two individuals who 
accidentally swallowed a small amount of a pure culture” of 
Salmonella Paratyphi A and who “became ill … five and seven 
days after imbibing” the culture [15]. Here, we describe the 
first deliberate and controlled human challenge model using 
a contemporary circulating strain of S. Paratyphi A. Although 
S. Typhi challenge studies have become well established over 
the past half-century, we have uniquely demonstrated that S. 
Paratyphi A challenge can also be undertaken safely in an out-
patient setting. Challenge at a target dose of 1–5 × 103 CFU was 
sufficient to achieve an attack rate of 60% in a cohort of naive 
volunteers, whereas challenge using a lower dose resulted in a 
reduced attack rate and increased time to bacteremia.
While Vi-conjugate typhoid vaccines are currently licensed in 
both India and China, the paratyphoid A vaccine pipeline is less 
well developed [6]. The effect of future Vi-based typhoid vaccine 
programs on the burden of paratyphoid fever is unknown and 
there is conflicting evidence of serovar replacement following 
historical typhoid vaccination campaigns [16, 17]. This presents 
a pressing need for accelerated paratyphoid A  vaccine devel-
opment, which could be facilitated by the establishment of a 
human paratyphoid A challenge model. In support of this, the 
World Health Organization has stated that well-validated chal-
lenge studies can provide “considerable supporting evidence of 
the efficacy” of typhoid Vi-conjugate vaccines, as well as offering 
insights into immunological correlates of protection [18]. We 
suggest that the model described herein could fulfill an equiv-
alent role for paratyphoid by providing a platform to assess the 
efficacy of paratyphoid vaccines currently in development.
The choice of diagnostic endpoints is central to future appli-
cations of this model in the assessment of candidate paratyphoid 
vaccines. In this study, we used a composite diagnostic end-
point of clinical and/or microbiologically defined paratyphoid 
infection and observed that 95% of individuals who met the 
diagnostic criteria did so based upon microbiological criteria 
(Table 2). The frequency of blood culture sampling in this study 
resulted in the identification of several cases of asymptomatic 
Figure 2. Comparison of the clinical and microbiological response to Salmonella Typhi and Salmonella Paratyphi A challenge. A, Solicited systemic symptoms in individuals 
with acute typhoid (n = 24) or paratyphoid (n = 20) disease recorded using an online diary (day 0, day of challenge; day 14, final day of treatment initiation). Percentage of 
participants reporting 1 or more events. Stacked columns display percentage of participants reporting maximum symptom severity as mild (present but no limitation of usual 
activity), moderate (some limitation of daily activity), or severe (unable to perform normal daily activity). B, Comparison of cumulative symptom severity scores between 
participants with acute typhoid (n = 24) or paratyphoid (n = 20) disease. Symptom scores were calculated by summing numerical values assigned to the severity of individual 
symptoms between day 0 and day 14 (0, not present; 1, mild; 2, moderate; 3, severe). Box-and-whisker plots display median, interquartile range, and range. C, Symptom 
severity scores for specific symptoms, day 0 to day 14. D, Results of quantitative blood cultures collected immediately prior to initiation of antibiotic treatment for participants 
with typhoid or paratyphoid disease (see Materials and Methods). Abbreviations: CFU, colony-forming units; N & V, nausea and vomiting; P, paratyphoid; T, typhoid. 
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bacteremia, which may or may not have progressed to sympto-
matic paratyphoid fever if left untreated. While the consistent 
finding of bacteremia represents an unambiguous diagnos-
tic endpoint, this could set an overly stringent threshold in 
future vaccine efficacy studies, and clinical endpoints might be 
preferable as this more accurately reflects the situation in the 
field (Table 2). Arguably, vaccines demonstrating at least mod-
erate efficacy in this challenge model would perform better in 
field trials, where the endpoints would include a clinical syn-
drome of paratyphoid fever with culture confirmation. Vaccine 
Figure 3. Clinical and microbiological dynamics for participants challenged with Salmonella Typhi and Salmonella Paratyphi A. A, Pattern of blood culture results (red, 
positive; gray, negative; white, sample not collected). Numbers in parentheses refer to quantitative blood culture colony count (colony-forming units/mL) taken immediately 
prior to antibiotic treatment and correspond to day of treatment initiation. B, Pattern of stool shedding following challenge. Colored squares indicate stool culture results for 
S. Paratyphi A or S. Typhi (brown, positive; gray, negative; white, sample not collected). C, Maximum temperature (temp., °C) measurements by day. Abbreviations: day 0, day 
of challenge; nPD1–20, paratyphoid disease not diagnosed; nTD1–16, typhoid disease not diagnosed; PD1–20, confirmed paratyphoid disease; TD1–25, confirmed typhoid 
disease; Tx, day of treatment initiation.
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efficacy studies using this model should include multiple alter-
native prespecified secondary diagnostic endpoints, such as 
the proportion of cases diagnosed by clinical criteria alone or 
microbiological criteria alone or a composite of clinical symp-
toms with culture confirmation.
To our knowledge, no previous studies have explored 
the infectious dose required to induce paratyphoid dis-
ease, although it is frequently assumed that S. Paratyphi 
A requires a higher dose of bacteria to cause clinical disease 
than does S. Typhi [19, 20]. In this study, an attack rate of 
60% was achieved using a dose of 1–5 × 103 CFU S. Paratyphi 
A, which is comparable to the attack rate (55%) observed at 
an equivalent dose of S. Typhi in earlier studies [11]. Notably, 
challenge with as few as 700 CFU S. Paratyphi A  was able 
to induce acute disease, in the context of sodium bicarbo-
nate pretreatment. Our findings are broadly consistent with 
observations from S. Typhi challenge studies, where reduc-
ing the challenge inoculum results in a reduced attack rate 
and longer incubation period [21]. As with S. Typhi, it is 
possible that the infectious dose required to induce paraty-
phoid disease in a nonendemic setting may differ from that 
required in an endemic setting, where prior exposure could 
lead to partial immunity.
We performed a post hoc comparison of symptom data col-
lected during earlier typhoid challenge studies [11] and noted 
that paratyphoid challenge resulted in a milder disease profile 
than that previously observed following typhoid challenge. 
In our model, paratyphoid was characterized by high rates 
of afebrile bacteremia in groups 1 and 2 (11/20 [55%]) with 
minimal symptoms, which may otherwise have escaped detec-
tion in the absence of intensive sampling. Case series from the 
preantibiotic era reported that S. Paratyphi A caused a spec-
trum of clinical manifestations that “closely resembles that of 
mild enteric fever” [22], and asymptomatic cases of paraty-
phoid infection are well described [23, 24]. Although the larg-
est published case series to date indicates that S. Typhi and 
Paratyphi A infections cause an indistinguishable clinical syn-
drome [19], this study was limited to patients who attended 
healthcare facilities and may not account for ambulatory or 
mild cases of paratyphoid in the community. In keeping with 
this, epidemiological data from endemic settings suggest that 
subclinical paratyphoid infection frequently occurs [5]. In 
light of our challenge model data, we interpret earlier data as 
being supportive of the hypothesis of an underappreciated and 
undiagnosed burden of paratyphoid disease in the commu-
nity. In a proportion of individuals, exposure to the bacillus is 
followed by asymptomatic bacteremia and asymptomatic stool 
shedding, potentially perpetuating both long- and short-cycle 
transmission. In keeping with this, asymptomatic shedding of 
S. Paratyphi A was also observed in our model, including in 
individuals who did not meet diagnostic criteria for paraty-
phoid disease.
Somewhat counterintuitively, we observed prolonged bac-
teremia and protracted time to blood culture clearance (≥96 
hours) in the paratyphoid challenge model, despite the low 
rate of fever. In addition, convalescent stool shedding was 
noted in 2 individuals despite a 14-day course of ciprofloxacin, 
both of whom were successfully treated with a further course 
of azithromycin. The relatively poor response to ciprofloxacin 
was unexpected, given that the NVGH308 strain is sensitive 
to ciprofloxacin according to current Clinical and Laboratory 
Standards Institute and European Committee on Antimicrobial 
Susceptibility Testing guidelines (minimum inhibitory con-
centration [MIC] = 0.06 μg/mL) [25, 26]. Studies in endemic 
settings have found that fluoroquinolone MICs for S. Paratyphi 
A were typically higher than those for S. Typhi [19]. The mech-
anisms underlying the discrepancy between the clinical and 
microbiological profiles of paratyphoid infection seen in this 
study are unclear, but may represent a strategy of achieving 
infection-by-stealth that facilitates onward transmission and 
persistence of the bacterium within the environment.
Ethical and safety considerations in the design of this study, 
including early initiation of rescue therapy, limit the extent to 
which our findings can be extrapolated to endemic settings. 
For example, a proportion of individuals with subclinical bac-
teremia could have progressed to symptomatic disease had 
antibiotic treatment been delayed, as was observed in histor-
ical typhoid challenge studies (W. E. Woodward, unpublished 
monograph). As only a single strain was used in this study, 
we cannot conclusively rule out a strain-specific effect for our 
observations. However, the NVGH308 strain is a recent clin-
ical isolate from a symptomatic case with bacteremia, and is 
closely related to currently circulating strains in South Asia. 
Additionally, S. Paratyphi A  is a clonal monomorphic patho-
gen containing limited genomic variation, suggesting that the 
pathogenicity and immune response to the NVGH308 strain 
will translate to other wild-type strains [27]. Future work could 
identify whether these observations apply to other strains of S. 
Paratyphi A and also investigate B and C strains in the human 
challenge model. The evaluation of only 2 challenge doses is one 
potential limitation of this study, and challenge at of higher dose 
ranges and/or rechallenge studies could be undertaken to better 
define clinical outcomes.
In summary, we have established the first S. Paratyphi 
A human challenge model and have described the clinical and 
microbiological response to challenge in healthy adult volun-
teers, presenting marked differences from those previously seen 
with S. Typhi. While S. Typhi challenge models have existed for 
several decades, the need for a S. Paratyphi A challenge model 
arguably exceeds that for S. Typhi, as far less is understood 
regarding the responses to infection and there are no specific 
control measures yet available. Development of a successful 
paratyphoid challenge model could offer distinctive insights 
into paratyphoid disease as well as providing a platform to 
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expedite the development and implementation of much-needed 
vaccines and diagnostics.
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